Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Emgality (Galcanezumab) 120 mg
Emgality, containing Galcanezumab at a 120 mg dosage, is a specialized treatment for migraine prevention in adults. It offers a targeted approach by inhibiting CGRP, a key protein in the migraine cascade, providing relief to those suffering from frequent migraines.
Uses of Emgality (Galcanezumab) 120 mg
Migraine Prevention: Used to prevent migraine attacks in adults, reducing the frequency and severity of episodes.
Chronic Migraine Management: Helps in managing chronic migraine conditions, improving the quality of life for those with frequent migraines.
Benefits of Emgality (Galcanezumab) 120 mg
Targeted Treatment: Specifically designed to target and inhibit CGRP, a protein that plays a significant role in migraine development.
Reduces Migraine Frequency: Clinical studies have shown significant reductions in the number of migraine days per month.
Improves Quality of Life: Helps patients regain control over their lives by reducing the burden of migraine attacks.
Well-Tolerated: Generally well-tolerated with a favorable side effect profile, making it suitable for long-term use.
Convenient Dosage: Administered as a once-monthly subcutaneous injection, simplifying the treatment regimen.
Mechanism of Action of Emgality (Galcanezumab) 120 mg
Galcanezumab: The active ingredient, Galcanezumab, is a monoclonal antibody that selectively binds to the calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis. By binding to CGRP, Galcanezumab prevents it from interacting with its receptors, thus inhibiting the cascade of events that lead to migraine attacks. This targeted action reduces the frequency and severity of migraines, offering relief to patients who suffer from this debilitating condition.